Multicenter study shows that sequential therapy improves survival in EGFR-mutant non-small cell lung cancer, suggesting a promising treatment approach.
Sequential afatinib-to-osimertinib therapy achieved remarkable OS exceeding 55 months in real-world practice, with outcomes appearing competitive with contemporary combination strategies. These findings support sequential TKI therapy as a durable and effective alternative that warrants prospective validation.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: